Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 274-778-7 | CAS number: 70693-62-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2001-01-04 - 2001-09-03
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- March 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- September 1996
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Pentapotassium bis(peroxymonosulphate) bis(sulphate)
- EC Number:
- 274-778-7
- EC Name:
- Pentapotassium bis(peroxymonosulphate) bis(sulphate)
- Cas Number:
- 70693-62-8
- Molecular formula:
- H3K5O18S4
- IUPAC Name:
- pentapotassium bis((hydroperoxysulfonyl)oxidanide) hydrogen sulfate sulfate
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan U. K. Ltd., Bicester, Oxon, UK
- Age at study initiation: 5 - 7 weeks
- Weight at study initiation: 108 g (males); 88.5 g (females)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 2 % w/v and 20 % w/v (corresponding to 20 mg/mL and 200 mg/mL, respectively)
- Total volume applied: 10 mL/kg bw - Doses:
- 200 mg/kg bw (3 males; 3 females) + 2000 mg/kg bw (3 females)
- No. of animals per sex per dose:
- 3 rats per sex and group
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Examinations:
* clinical observations: at frequent intervals during test day 1, twice daily during days 2 – 15; all abnormalities were recorded
* mortality/viability: at least twice daily
* body weight: on test day 1 (prior to administration), 8 and 15
* necropsy (day 15): macroscopical examination of all animals (survivors and decedents) which consisted of opening the cranial, thoracic and abdominal cavities. The macroscopic appearance of all examined organs was recorded. - Statistics:
- Toxicity was estimated without use of a statistical model.
Further more, when applying OECD 423 (Acute Toxic Class Method) for the determination of the acute oral LD50, a statistical method is not considered to be required, as this particular method does not yield the determination of an accurate LD50 figure but apart from specific situations gives rather an estimate on the range of the LD50.
Results and discussion
- Preliminary study:
- not indicated
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Since no deaths occurred at a dose level of 200 mg/kg bw and all animals died after the administration of 2000 mg/kg bw the LD50 (oral) was determined to be 500 mg/kg bw according to OECD 423 Annex 2c.
- Clinical signs:
- other: - Both dosages/all rats: piloerection, first noted approximately one hour after dosing - 200 mg/kg bw: no further signs of toxicity observed - 2000 mg/kg bw: all females showed hunched posture, lethargy, abnormal gait, reduced body temperature, body tremo
- Gross pathology:
- - All females treated with 2000 mg/kg bw died (two animals were found dead 6 h after administration, one on day 2). The animals revealed congestion in the subcutaneous tissue, brain, heart, lungs and spleen with pallor of the kidneys and pale patches on the liver and red fluid contents of the urinary bladder in one or more animals. Congestion and fluid contents were noted in the stomach and along the alimentary tract and in the urinary tract with enlarged, swollen or thickened tissues and dark and pale discolouration of the lining also seen in the stomach for all animals.
- No abnormalities were revealed for surviving animals. - Other findings:
- not indicated
Any other information on results incl. tables
Table 1: Mortality data
Dose | No. of deaths in group of 3 | Day* | ||
- | - | 1 | 2 | 3 to 14 |
200 | 0/3 Male | 0 | 0 0 | 0 0 |
2000 | 3/3 Female | 2 | 1 - | - - |
* The day/time indicated is the time that the animal was observed to die or found dead.
a First observation
b Second observation
- Not applicable
Table 2: Signs of reaction to treatment
Clinical signs | No. of rats in groups of 3 showing signs | ||
200 | 2000 | ||
Male | Female | Female | |
Piloerection | 3 | 3 | 3 |
Hunched posture | 0 | 0 | 3 |
Lethargy | 0 | 0 | 3 |
Abnormal gait | 0 | 0 | 3 |
Reduced body temperature | 0 | 0 | 3 |
Body tremors | 0 | 0 | 3 |
Shallow respiration | 0 | 0 | 3 |
Pallor of the skin | 0 | 0 | 3 |
Dull eyes | 0 | 0 | 2 |
Partially closed eyelids | 0 | 0 | 1 |
Red staining around the uro/genital area | 0 | 0 | 1 |
|
|
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The study and the conclusions which are drawn from it fulfill the quality criteria (validity, reliability, repeatability). Since no deaths occurred at a dose level of 200 mg/kg bw and all animals died after the administration of 2000 mg/kg bw the LD50 (oral) was determined to be 500 mg/kg bw according to OECD 423 Annex 2c. Based on Regulation 1272/2008/EC (CLP), KMPS triple salt is classified as harmful if swallowed (cat. 4 (H302)).
- Executive summary:
Materials and methods
Six (three male and three female) Sprague Dawley (CD) rats received a single dose of 200 mg KMPS triple salt/kg bw and another group of three females received 2000 mg KMPS triple salt/kg bw. The substance was administered by gavage at a constant volume of 10 mL/kg bw in distilled water as the vehicle. Animals were fastened over night prior to administration of the test material. Post-observation period was 14 days. A regular examination on clinical signs of toxicity and mortality/viability was performed. Body weights were determined pre-treatment on day 1, on days 8 and 15, or at death. All animals were subjected to a macroscopic examination on day 15.
Results and discussion
Please refer to tables 1 and 2, which are presented under "Remarks on results including tables and figures".
Following a single oral administration of KMPS triple salt by gavage to male and female Sprague Dawley (CD) rats at dose levels of 200 + 2000 mg/kg bw, all three females dosed with 2000 mg/kg bw died (two approximately 6 hours after dosing and one within 22 hours of dosing). A body weight loss was recorded for two of the decedents. Clinical signs at the 2000 mg/kg bw dosage were characterised by hunched posture, lethargy, abnormal gait, reduced body temperature, body tremors, shallow respiration and pallor of skin with dull eyes in two females and partially closed eyelids and red staining around the uro/genital area in one female. The animals revealed congestion in the subcutaneous tissue, brain, heart, lungs and spleen with pallor of the kidneys and pale patches on the liver and red fluid contents of the urinary bladder in one or more animals. Congestion and fluid contents were noted in the stomach and along the alimentary tract and in the urinary tract with enlarged, swollen or thickened tissues and dark and pale discolouration of the lining also seen in the stomach for all animals. No signs of toxicity (except of piloerection) observed were observed in animals of the 200 mg/kg bw dose group.
Recovery of surviving rats, as judged by external appearance and behaviour, was complete by day 3. No abnormalities were revealed for surviving animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.